RxDoctor Payments Data

Chris Doerr

Psychiatric/Mental Health, Adult · Paramus, NJNPI 1003990771

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $534 of the $597 with a category attached, or 89.4%. 9 manufacturers reported payments, led by Alkermes, Inc. at 33.5% of the total. Reporting peaked in 2021 at $232 and has fallen 54.7% since, to $105 in 2025.

$597in general payments, 2019–2025

Across 20 payments — averaging $29.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$200
  • Neurocrine Biosciences, Inc.$161
  • Johnson & Johnson$81
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$39
  • Acadia Pharmaceuticals Inc$35
  • Otsuka America Pharmaceutical, Inc.$34
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$53489%
  • Education$6311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$597 in reported general payments places this provider in the 70th percentile of 35 psychiatric/mental health, adult providers in New Jersey.

See all psychiatric/mental health, adult providers in New Jersey

Medicare billing

Part B allowed, 2024
$42,007
Medicare patients
73
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate190$583,791
Abilify MaintenaAripiprazole39$93,615
ClozarilClozapine48$42,383
LybalviOlanzapine/Samidorphan Malate25$40,954
Clozapine497$28,430
ZyprexaOlanzapine12$14,982
Olanzapine358$7,920
Divalproex Sodium ErDivalproex Sodium112$6,074
ZoloftSertraline Hcl12$4,963
Clonazepam317$4,458
Clozapine OdtClozapine19$4,258
Olanzapine OdtOlanzapine85$2,930
Paroxetine Hcl195$2,892
Benztropine Mesylate272$2,671
Fluphenazine Hcl54$2,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$81$583,791190 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$34$93,61539 claims
Alkermes, Inc.Lybalvi$200$40,95425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 psychiatric/mental health, adult providers in New Jersey.

Other psychiatric/mental health, adult in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →